ProgenyHealth Releases 2026 Maternal & Infant Health Trends Report
Report identifies 5 emerging trends within maternal and infant health and what they reveal about the state of the industry now...
Vaccine
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use
Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding...
IO Biotech Announces Exploration of Strategic Alternatives
NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf...
Abcam joins the Innovative Health Initiative LIGAND-AI project to advance artificial intelligence (AI)-driven drug discovery through open science
Abcam has joined an industry-academic partnership led by the Structural Genomics Consortium and Pfizer to advance AI-driven drug discovery through...
Abcam joins the Innovative Health Initiative LIGAND-AI project to advance artificial intelligence (AI)-driven drug discovery through open science
Abcam has joined an industry-academic partnership led by the Structural Genomics Consortium and Pfizer to advance AI-driven drug discovery through...
Abcam joins the Innovative Health Initiative LIGAND-AI project to advance artificial intelligence (AI)-driven drug discovery through open science
Abcam has joined an industry-academic partnership led by the Structural Genomics Consortium and Pfizer to advance AI-driven drug discovery through...
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)
Study subject Remains in Complete Response for 3 YearsExceeds Expectations in Platinum-Resistant Ovarian Cancer Compared to Standard of Care Single-Agent...
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
At a median five-year pre-planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA reduced the...
Statement from Unity Consortium on Announced Changes to the U.S. Childhood and Adolescent Immunization Schedule
VENTNOR CITY, N.J., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Unity Consortium recognizes that recent changes to the U.S. childhood and...
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
Preliminary total global full year 2025 revenue of approximately $616 million Preliminary BRIUMVI U.S. fourth quarter and full year 2025...
Nu-Tek BioSciences Reinforces Global Supply Leadership with Halal Certification Renewal
Nu-Tek Manufacturing Facility Nu-Tek's state-of-the-art facility, purpose built to provide over 2000 metric tons of animal-free production annually. Nu-Tek BioSciences...
NanoViricides Comments on the Need for Broad-Spectrum Antivirals in Light of the Current Influenza Wave – NV-387 is Effective Against H3N2
SHELTON, CONNECTICUT / ACCESS Newswire / January 13, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
Evaxion expands AI-Immunology™ platform into autoimmune diseases
Evaxion adds autoimmune disease as a third disease area as it expands its therapeutic focusIn future, Evaxion’s proprietary AI-Immunology™ platform...
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
January 13, 2026, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company...
Using Recombinant Insulin and Trypsin for Safer Vaccine Production, Upcoming Webinar Hosted by Xtalks
In this free webinar, learn how recombinant insulin improves viral production across diverse vaccine platforms. Attendees will gain insight into...
Commonwealth Fusion Systems Names Stephane Bancel to Board of Directors
DEVENS, Mass., Jan. 12, 2026 /PRNewswire/ -- Commonwealth Fusion Systems (CFS), the largest and leading private fusion company, today announced...
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings CallImproves 2025 expected GAAP...
Cellev8 Nutrition Welcomes Dr. Guangshuo “Alan” Zhu, MD to Its Board of Directors
WELLINGTON, FLORIDA / ACCESS Newswire / January 8, 2026 / Cellev8 Nutrition Inc., (OTCID:CELV) a leader in clinically validated antioxidant...
Ascend Advanced Therapies – ABL Inc. Further Strengthens Executive Team as It Drives Forward an Ambitious Growth Strategy
Seiga Ohmine to join as Chief Commercial Officer, Sharad Dubey as Chief Financial Officer and Patrick Lansky as Senior Vice...
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or...